AU · rank #4 · 2026-10-22
ATEC
NASDAQ · $1.68B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 2.841 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.00 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) $1,013,150 across 1 unique buyers. | 3.000 |
| Analyst upside Consensus target $15.79 | +45.4% |
| Momentum acceleration 3-month minus 12-month momentum. | +39.15% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.79 |
| Gross margin TTM | +70.8% |
| 52w high | $23.29 |
| Market cap (USD) | $1.68B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Alphatec Holdings Inc designs and markets integrated spinal surgery solutions, combining implants, biologics, SafeOp neuromonitoring, EOS imaging, and the Valence navigation and robotics platform.
Rationale
The analyst upside signal (45.4% price upside, 4.79/5 rating) is supported by 20% surgical case-volume growth, 24% net-new surgeon adoption, $1.01 million in insider buying, and raised full-year 2026 EBITDA guidance to $140 million.
Material risks
- 1A heavy debt load of $510.7 million against $119 million in cash creates financial sensitivity if surgical revenue per case or cash flow conversion slows.
- 2Well-capitalized spine competitors including Medtronic, Globus Medical, and Stryker can leverage deep hospital contracting relationships to bundle competing imaging, navigation, and implant platforms.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.